The pharmaceutical company said in a regulatory filing to the BSE that it will market the sofosbuvir 400 mg/velpatasvir 100 mg fixed dose combination in India under the brand name 'Velpanat'.
According to the company, the product is the generic version of the fixed dose combination sold by Gilead Sciences globally under the brand name 'Epclusa'.
"Epclusa is the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection," the BSE filing said.
The company said the generic drug is priced at Rs 18,500 for a bottle of 28 tablets in India.
"Natco has signed a non-exclusive licensing agreement with Gilead Sciences, Inc., to manufacture and sell generic versions of its chronic hepatitis C medicines in 101 developing countries," the company added.
(This story has not been edited by Social News XYZ staff and is auto-generated from a syndicated feed.)
Doraiah Chowdary Vundavally is a Software engineer at VTech . He is the news editor of SocialNews.XYZ and Freelance writer-contributes Telugu and English Columns on Films, Politics, and Gossips. He is the primary contributor for South Cinema Section of SocialNews.XYZ. His mission is to help to develop SocialNews.XYZ into a News website that has no bias or judgement towards any.
This website uses cookies.